Polygenic Score May Identify Kids, AYAs With AML Who Need Augmented Therapy
A low score was associated with poor outcomes in patients who received standard induction therapy.
Pediatric Cancer
Inotuzumab Ozogamicin Deemed Effective in Heavily Pretreated B-ALL
The estimated event-free survival rate was 28.6% at 2 years and 19.6% at 3 years.
Psychological Distress More Likely in Young Adult Cancer Survivors
Roughly 11% of AYA cancer survivors reported psychological distress 20 years or more after their cancer diagnosis.
Maternal Hormonal Contraception, CNS Tumors Not Linked in Children
No significant association was seen between maternal hormonal contraception use and CNS tumors in children younger than 20 years.
Reinfusion of CAR-T Cells May Prevent Relapse in Acute Lymphoblastic Leukemia
The findings of this study prompted a change in clinical practice.
Adding Monoclonal Antibody to Induction Could Be New Standard Care for High-Risk Neuroblastoma
Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.
Study Reveals ‘Best Biomarker to Date’ for Predicting Relapse After CAR T-Cell Therapy
Minimal residual disease in the bone marrow, detected via next-generation sequencing, was “highly predictive” of relapse after treatment with tisagenlecleucel.
Blinatumomab Plus Chemo: ‘New Standard’ for Some Low-Risk Patients With First Relapse of B-ALL
Blinatumomab improved disease-free and overall survival.
FDA Approves Rituxan Plus Chemotherapy for Certain Pediatric Hematologic Cancers
The approval was based on data from the open-label, randomized phase 3 Inter-B-NHL Ritux 2010 trial.
Caregivers of Childhood Cancer Survivors Concerned About COVID-19 Vaccines
Concerns, expressed early in the rollout, included lack of safety and efficacy data, particularly in children with cancer.
- Loading...
Loading...
Next post in Pediatric Cancer
Loading... 
Loading...